Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented ...

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes.

The system is inconspicuous and easy to use and has so far been very successful among patients new to insulin pumps. Omnipod has helped materially increase penetration of pumps among type 1 patients.

Tandem Diabetes Care announced that the FDA cleared its Control-IQ+ automated insulin delivery algorithm for people with type ...

Type 1 Diabetes Market Rising Prevalence and Technological Advancements Drive Market Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...